Korean J Dermatol.
2010 Oct;48(10):872-875.
Erlotinib HCL (Tarceva(R)) Induced Radiation Recall Dermatitis
- Affiliations
-
- 1Department of Dermatology, School of Medicine, Gyeongsang National University, Jinju, Korea. cykim@gnu.ac.kr
- 2The Gyeongsang Institute of Health Science, Jinju, Korea.
Abstract
- Erlotinib (Tarceva(R)) is a new anti-cancer agent that acts by inhibiting epidermal growth factor receptor (EGFR) signal transduction. It is currently used in the treatment of advanced stage non-small cell lung cancer and pancreatic cancer. A patient consulted our clinic and she had erythematous patches and vesicles on the submandibular area. She had taken erlotinib for the treatment of recurred lung cancer for 2 weeks. We report here on a case of radiation recall dermatitis that was induced by erlotinib in a 69-year-old woman who was previously irradiated on her submandibular area.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Acneiform Eruption Induced by Erlotinib (Tarceva(R))
- A case of cetuximab-induced radiation recall skin dermatitis and review of the literature
- Erlotinib (Tarceva(R)) Induced Hair Abnormalities
- A Case of Acneiform Eruption and Paronychia Occurring after Use of Erlotinib (Tarceva(R))
- Two Cases of Acneiform Eruption Caused by Epidermal Growth Factor Receptor Inhibitors
